Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misleading investors regarding its accounts receivable and financial reporting practices [1][2]. Group 1: Allegations - Ardent Health reportedly inflated its accounts receivable and delayed recognizing losses on uncollectable accounts during the class period [2]. - The company did not maintain sufficient professional malpractice liability insurance to cover claims arising from its operations [2]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, leading to a significant stock price drop of nearly 34% [2]. Group 2: Legal Proceedings - Shareholders who purchased Ardent Health securities between July 18, 2025, and November 12, 2025, may be eligible to participate in the class action [1][3]. - Interested shareholders can contact Robbins LLP to serve as lead plaintiff, representing other class members in the litigation [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misrepresenting its accounts receivable collection practices, leading to inflated financial results during the class period from July 18, 2024, to November 12, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ardent stated it used an active monitoring process for accounts receivable collectability, but actually relied on a 180-day cliff method, which allowed for higher reported accounts receivable and delayed loss recognition [1] - Investors who suffered losses on Ardent investments have until March 9, 2026, to request lead plaintiff appointment [1] Group 2: Financial Impact - On November 12, 2025, Ardent announced a $43 million reduction in revenue due to changes in accounting estimates for accounts receivable collectability and a $54 million increase in professional liability reserves related to claims in New Mexico [2] - Following this announcement, Ardent's share price fell by $4.75, or approximately 33.8%, from $14.05 to $9.30 per share [2]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for misrepresentations regarding its accounts receivable during the Class Period from July 18, 2024, to November 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ardent Health made false statements about its accounts receivable management, including the reliance on "detailed reviews of historical collections" and the adequacy of its professional malpractice liability insurance [5]. - Defendants allegedly downplayed the issue of increased claim denials by third-party payors, misrepresenting the situation as a "slow pay" issue rather than acknowledging uncollectible accounts [5]. - The lawsuit asserts that Ardent Health's accounts receivable framework allowed for inflated reporting, delaying the recognition of losses on uncollectible accounts [5]. Group 2: Investor Information - Investors who purchased Ardent Health securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by March 9, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years [4].

Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. following significant adverse accounting adjustments of approximately $90 million, leading to a stock price decline of over 33% [1] Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired Ardent securities between July 18, 2024, and November 12, 2025 [1] - The lead plaintiff deadline for the lawsuit is set for March 9, 2026 [3] - The case is titled Postiwala v. Ardent Health, Inc. et al., No. 3:26-cv-00022 (M.D. Tenn.) [3] Group 2: Allegations and Investigations - Hagens Berman is investigating claims that Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves [2] - The complaint alleges that timely writing off uncollectible accounts is crucial to avoid inflating accounts receivable [4] - The lawsuit claims that Ardent misled investors regarding its reliance on detailed reviews of historical collections for determining accounts receivable collectability [5] Group 3: Financial Disclosures and Market Reaction - On November 12, 2025, Ardent disclosed a $42.6 million decrease in revenue due to changes in accounting estimates and new information from hindsight evaluations [6] - The company's CFO revealed that a 180-day cliff was used for reserving accounts, contradicting earlier assurances about the collection procedures [6] - Following the disclosures, Ardent's stock price fell by $4.75, a decline of 33% [6] Group 4: Implications and Further Actions - The significant revenue reduction and reserve increase raise questions about whether these issues should have been disclosed earlier [7] - Hagens Berman encourages investors who suffered losses to contact the firm for potential recovery options [7]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Ardent Health, Inc. ("Ardent†or the "Company†) (NYSE: ARDT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ARDENT HEALTH, INC. (ARDT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On November 12, 2025, after market hours, Ardent released its third. ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Ardent Health, Inc. for allegedly misleading investors about its business operations and accounts receivable practices during the period from July 18, 2024, to November 12, 2025 [1][2]. Allegations - The lawsuit claims that Ardent Health misrepresented its accounts receivable, stating that it employed an active monitoring process for collectability, which included detailed reviews of historical collections [3]. - Defendants allegedly downplayed the issue of increased claim denials by third-party payors, framing it as a slow payment issue rather than uncollectibility, and did not write off uncollectible accounts [3]. - Contrary to their claims, Ardent Health reportedly did not rely on detailed reviews for determining collectability and instead utilized a 180-day cliff for reserving accounts, allowing for inflated accounts receivable reporting [3]. - The company also allegedly lacked sufficient professional malpractice liability insurance to cover claims, particularly in the context of increasing social inflationary pressures in medical malpractice cases in New Mexico [3]. Next Steps - Shareholders interested in participating in the class action must file motions to serve as lead plaintiff by March 9, 2026, although participation is not required for recovery eligibility [4].

Core Viewpoint - A shareholder class action lawsuit has been filed against Ardent Health, alleging that the company issued false and misleading statements regarding its accounts receivable practices, specifically that it did not primarily rely on detailed reviews of historical collections to determine collectability [1] Group 1 - The lawsuit claims that Ardent Health's accounts receivable framework utilized a 180-day cliff for reserving accounts, which allowed the company to report inflated accounts receivable and delay recognizing losses on uncollectible accounts [1] - The class period for the lawsuit is defined as between July 18, 2024, and November 12, 2025, targeting investors who experienced significant losses during this timeframe [2] - The deadline for potential lead plaintiffs to file their applications is March 9, 2026 [3]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a 180-day cliff method for reserving accounts [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it allows purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025, to seek lead plaintiff status by March 9, 2026 [1]. - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable, which inflated its reported financial position [3]. - Allegations include that Ardent Health's accounts receivable framework allowed for delayed recognition of losses, and that the company lacked sufficient malpractice liability insurance [3]. Group 2: Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third quarter revenue due to revised accounts receivable assessments and a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ardent Health securities during the class period to seek lead plaintiff status, which enables them to represent the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after transitioning to a new revenue accounting system [3]. - The new accounting system, Kodiak RCA net revenue platform, allows for more precise determination of accounts receivable collectability and recognizes reserves earlier in an account's life cycle compared to the previous framework [3]. - Ardent also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [3]. - Additionally, the company recorded a $54 million increase in professional liability reserves related to recent settlements and ongoing litigation, influenced by broader industry trends [3]. - Following these announcements, Ardent's stock price fell by $4.75 per share, or 33.81%, closing at $9.30 per share on November 13, 2025 [3].